Routine share withholding; mechanical by default.
Loading…
Traded Apr 9, 2026 · Filed Apr 9, 2026
The money chief of Edwards Lifesciences sold $376K of Edwards Lifesciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$376,401
Shares × reported transaction price
58 days after results of Feb 10, 2026, 14 days before results of Apr 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $79.15 on Apr 9, 2026, 16% above its 52-week low and 9% below its high, after a 5% drop over the previous 30 trading days
52-week range $68.26 (Apr 10, 2025) to $87.18 (Mar 2, 2026), 58% of the way up, from 250 adjusted closes. 30 trading days earlier: $83.40 on Feb 25, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.0% | +4.5% | -0.5% |
| 30 days | -0.9% | +8.8% | -9.7% |
| 90 days | +17.3% | +10.6% | +6.7% |
Past results only. Not a forecast.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.